Summary & Overview
HCPCS A4802: Protamine Sulfate for Hemodialysis, per 50 mg
HCPCS Level II code A4802 denotes protamine sulfate, supplied for hemodialysis in 50 mg units. Protamine sulfate is used clinically to neutralize heparin after dialysis or to reverse anticoagulation in patients receiving heparin during extracorporeal treatments. Nationally, accurate coding for this medication matters for facility supply tracking, reimbursement for dialysis centers, and clinical documentation linking anticoagulation reversal to procedural care.
This publication covers payer approaches from major national plans including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how A4802 is used in billing lines, typical sites of service, and which payers are commonly involved in coverage and payment for dialysis-related medication supplies. The report also outlines benchmarks and common billing practices, summarizes any notable policy considerations affecting supply billing for hemodialysis, and provides clinical context about when protamine sulfate is administered during dialysis care.
Intended for coding professionals, dialysis facility administrators, and clinical billing staff, the summary highlights operational implications of accurate HCPCS Level II coding, how A4802 integrates with hemodialysis service lines, and where to look for payer-specific coverage guidance. Data not available in the input is identified where applicable.
Billing Code Overview
HCPCS Level II code A4802 describes protamine sulfate, for hemodialysis, per 50 mg. This code represents a specific pharmaceutical supply used to neutralize heparin anticoagulation during or after hemodialysis procedures. The service type is medication administration/supply related to dialysis anticoagulation management. The typical site of service is outpatient dialysis centers and hospital dialysis units where hemodialysis is performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving hemodialysis for end-stage renal disease who requires reversal or neutralization of heparin anticoagulation at the end of a dialysis session or following an extracorporeal circuit clotting event. The patient arrives to an outpatient dialysis center or inpatient dialysis suite for a scheduled hemodialysis treatment. During the session, intravenous unfractionated heparin is administered to prevent clotting in the dialysis circuit. At the completion of dialysis or when an urgent need to reverse anticoagulation occurs (for example, excessive bleeding from an access site or need to perform an invasive procedure), protamine sulfate is prepared in a syringe and given intravenously per institutional protocol at a dose calculated to neutralize the previously administered heparin (commonly titrated and often expressed per 50 mg increments for billing). Vital signs and coagulation status are monitored before, during, and after administration. The typical site of service is an outpatient dialysis center, hospital inpatient dialysis unit, or emergency department when dialysis-related anticoagulation reversal is required. Documentation should include indication for reversal, amount of protamine administered (number of 50 mg units), timing relative to heparin dose, patient response, and any adverse reactions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstance modifier applies to the service. |
| | Increased procedural services | Use if administration required substantially greater resources or time than usual (document rationale).